The Addi Sinclair Immunotherapy Trial
Tumor-Infiltrating Lymphocyte Therapy for High-Risk Solid Tumors
High-risk types of malignant solid tumors in children (pediatric malignant solid tumors, pMST) have poor long-term cure rates, and new treatments are needed. Cell Therapy (ACT) with Tumor Infiltrating Lymphocytes (TIL) involves removal and growth and reinfusion of immune cells from a patient’s tumor back to the patient. This is a Phase I clinical trial of TIL-ACT in high-risk pMST to prove its safety and feasibility in children and report on responses seen with this therapy.
This Project By The Numbers
Years Active3 Years
InstitutionJohns Hopkins All Children’s Hospital